胰腺癌Conceptual Framework for Cutting the Pancreatic Cancer Fuel survival

2012;18:4285-4290.Clin Cancer ResAnne Le, N.V. Rajeshkumar, Anirban Maitra, et al.SupplyConceptual Framework for Cutting the Pancreatic Cancer FuelUpdated version/content/18/16/4285Access the most recent version of this article at:Cited Articles/content/18/16/4285.full.html#ref-list-1This article cites by 52 articles, 16 of which you can access for free at:Citing articles/content/18/16/4285.full.html#related-urls This article has been cited by 4 HighWire-hosted articles. Access the articles at:E-mail alertsrelated to this article or journal.Sign up to receive free email-alertsSubscriptionsReprints and.pubs@ To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department atPermissions.permissions@ To request permission to re-use all or part of this article, contact the AACR Publications Department atConceptual Framework for Cutting the Pancreatic Cancer Fuel SupplyAnne Le 1,N.V.Rajeshkumar 2,Anirban Maitra 1,2,and Chi V.Dang 3AbstractPancreatic ductal adenocarcinoma (a.k.a.pancreatic cancer)remains one of the most feared and clinically challenging diseases to treat despite continual improvements in therapies.The genetic landscape of pancreatic cancer shows near ubiquitous activating mutations of KRAS ,and recurrent inactivating muta-tions of CDKN2A ,SMAD4,and TP53.To date,attempts to develop agents to target KRAS to specifically kill cancer cells have been disappointing.In this regard,an understanding of cellular metabolic derangements in pancreatic cancer could lead to novel therapeutic approaches.Like other cancers,pancreatic cancer cells rely on fuel sources for homeostasis and proliferation;as such,interrupting the use of two major nutrients,glucose and glutamine,may provide new therapeutic avenues.In addition,KRAS -mutant pancreatic cancers have been documented to depend on autophagy,and the inhibition of autophagy in the preclinical setting has shown promise.Herein,the conceptual framework for blocking the pancreatic fuel supply is reviewed.Clin Cancer Res;18(16);4285–90.Ó2012AACR.IntroductionAlthough inherited and acquired mutations are believed to cause pancreatic cancer (see review by Iacobuzio-Dona-hue and colleagues in this issue;ref.1),common mutations in canonical oncogenes,such as AKT,MYC,PI3K,and RAS,and tumor suppressors,including TP53and PTEN,also alter cancer metabolism to enable cancer cells to survive and proliferate in the hypoxic and nutrient-deprived tumor microenvironment (see review by Feig and colleagues in this issue;ref.2).Oncogenes and tumor suppressors alter metabolism through transcriptional and posttranscription-al mechanisms.Mutations in genes encoding metabolic enzymes,such as succinate dehydrogenase (SDH),fumarate hydratase (FH),and isocitrate dehydrogenase (IDH)have also been linked to tumorigenesis,underscoring the inti-mate connections between metabolism and cancer (11,12).Loss-of-function SDH or FH mutations result in accumu-lation of precursors such as succinate or fumarate.Mutated IDH1or IDH2,on the contrary,are neomorphic enzymes that reverse the chemical reaction to produce 2-hydroxy-glutarate (2-HG)from a -ketoglutarate (a -KG;ref.13).These accumulated metabolic intermediates all have the ability to inhibit a -KG–dependent dioxgenases,which are involved in histone or DNA demethylation and in prolylhydroxylases that modulate the hypoxia-inducible factors (HIF;refs.14–16).In this regard,mutations in enzymes cause epigenetic deregulation that contributes to tumorigenesis.To survive and proliferate in an adverse tumor microen-vironment with limited nutrients and oxygen,cancer cells must rely on their ability to reprogram canonical biochem-ical pathways to provide the necessary bioenergetics and precursors of proteins,nucleic acids,and membrane lipids (17–19;Fig.1).In addition to rewiring metabolism,tumor cells can also activate autophagy,a process that permits recycling of cellular constituents as internal fuel sources when external nutrient supplies are limited (20–22).Although nutrient-rich conditions inhibit autophagy through activation of mTOR,nutrient-deprived conditions decrease ATP production,resulting in activated AMPK that stimulates autophagy (23,24;Fig.1).As such,cancer cells have multiple mechanisms for metabolic adaptation to the tumor microenvironment.Proliferating cancer cells transport glucose and glutamine into the cell as major nutrient sources for the production of ATP and building blocks for macromolecular synthesis (3,4,6;Fig.1).The mitochondrion serves not only as the cellular powerhouse,producing ATP efficiently from glu-cose and glutamine,but it is also a hub for the production of key intermediates involved in nucleic acid,fatty acid,and heme synthesis.The proliferating cancer cells,hence,also produce toxic by-products that must be eliminated or extruded for cell survival.Reactive oxygen species (ROS)from the mitochondrion are neutralized;superoxide is converted by SOD to hydrogen peroxide,which is neutral-ized by catalase via its conversion to water and oxygen (25–27).Lactate and carbon dioxide,produced from glucose and glutamine catabolism,are exported through monocar-boxylate transporters or neutralized and extruded byAuthors'Af filiations:Departments of 1Pathology and 2Oncology,The Sol Goldman Pancreatic Cancer Research Center,Johns Hopkins University School of Medicine,Baltimore,Maryland;and 3Abramson Cancer Center,Perelman School of Medicine,University of Pennsylvania,Philadelphia,PennsylvaniaCorresponding Author:Chi V.Dang,University of Pennsylvania,1600Penn Tower,3400Spruce Street,Philadelphia,PA 19072.Phone:215-662-3929;Fax:215-662-4020;E-mail:cvdang@ doi:10.1158/R-12-0041Ó2012American Association for CancerResearch. 4285carbonic anhydrase(28).Although this article focuses on blocking cancer fuel supply as a promising new approach to pancreatic cancer therapy,therapeutic opportunities may also exist in blocking the exhaust pipes that eliminate metabolic toxic by-products from cancer cells. Characteristic Features of Metabolism in CancersAberrant metabolism is now considered one of the hall-marks of cancer(29).As a result of genetic alterations and tumor hypoxia,cancer cells reprogram metabolism to meet increased energy demand for enhanced anabolism,cell proliferation,and protection from oxidative damage and cell death signals.The molecular underpinnings for the reprogrammed metabolism of cancer cells have been linked to the activation of oncogenes or loss of tumor suppressors, which can function independently of,or through constitu-tive stabilization of the HIF,HIF-1a.Activated Ras and AKT oncogenes can increase glycolysis,enhancing the conver-sion of glucose to lactate(3).The MYC oncogene,which encodes the transcription factor Myc,increases the expres-sion of glycolytic genes,thereby enhancing glycolysis and production of lactate(35).Glycolysis is a multienzymatic pathway that catabolizes glucose to pyruvate via more than a dozen different enzymes with several apparent rate-limiting steps.Phos-phofructose kinase provides thefirst rate-limiting step where fructose-1-phosphate,derived from glucose,is con-verted to fructose-1,6-bisphosphate.The other rate-limiting step is the conversion of phosphoenolpyruvate to pyruvate by pyruvate kinase(muscle form)PKM.Recent studies have raised an intense interest in the embryonic M2isoform of pyruvate kinase(PKM2),which is highly expressed in human tumors.A study by Gao and colleagues(30)showed that dimeric,not tetrameric PKM2that localizes the cellular nucleus,activates transcription of MEK5by phosphorylat-ing stat3at Y705using PEP as a phosphate donor.This protein kinase activity of PKM2plays a role in promoting cell proliferation,revealing an important link between metabolism alteration and gene expression during tumor transformation and progression.The xenografted adeno-carcinoma cells,which carry a mutant form of PKM2that preferentially forms dimers,grow more rapidly and seem more aggressive than cells carrying wild-type(WT)PKM2. Although the dynamics of PKM2oligomeric states and their roles in cancer remain confusing,these studies suggest that perturbation of glycolysis via manipulation of PKM2could have a significant therapeutic effect.Alteration of glucose metabolism in cancer is known as aerobic glycolysis or the Warburg Effect(3,5,31),which describes the ability of cancer cells to avidly metabolizeCCR Focus© 2012 American Association for Cancer Research MalateFumarateSuccinateOxaloacetateAcetyl-CoAPyruvateCitrateIsocitrateα-KetoglutarateNADPH riboseGlutathione nucleicacidsGlutaminolysis Glutamate GlutamineWarburg Effect LDHAGLSATP AMP BPTESAMPK Autophagy ChloroquineLactate Glycerol LipidsFatty acidsAcetyl-CoAFigure1.Diagram depicting themetabolism of glucose andglutamine via glycolysisand theTCA cycle.Both substratescontribute to the production ofATP,which when depleted wouldactivate AMPK that in turntriggers autophagy.Autophagyincreases lysosomal recycling ofcellular constituents to recoverATP.GLS,glutaminase.Clin Cancer Res;18(16)August15,2012Clinical Cancer Research 4286glucose to lactate,even in the presence of oxygen.A manifestation of the Warburg Effect is the increased 2[18F]fluoro-2-deoxy-D-glucose import by pancreatic can-cers as determined by positron emission tomographic(PET) scans.However,only about50%of pancreatic cancers have positive clinical PET,suggesting additional complexities and the possibility that pancreatic cancers could use other fuels or resort to other metabolic survival modes(32,33). In addition to glucose,proliferating cancer cells also rely on glutamine as a major source of energy and building blocks.In fact,MYC,which is frequently amplified or overexpressed in pancreatic cancer(34),has been mecha-nistically linked to the regulation of glutamine metabolism (35).In this regard,it is reasonable to surmise that PET negative pancreatic cancers may use glutamine as a major nutrient source.The Myc transcription factor emerges as a master regulator of a phlethora of genes involved in cell growth including those regulating ribosome and mitochon-drial biogenesis and intermediary metabolism.The normal MYC gene is under the scrutiny of many internal as well as extracellular cues such as nutrient and oxygen availability, such that deprivation of these supplies results in the downregulation of MYC expression.By contrast,many oncogenic pathways activate MYC or alterations of MYC itself resulting in a constitutive program of ribosome bio-genesis and biomass accumulation that renders cancer cells addicted to nutrients.Indeed withdrawal of either glucose or glutamine triggers death of cells with MYC overexpres-sion(35).In this regard,targeting enzymes involved in glucose or glutamine has also provided proof-of-concept that metabolic inhibition could provide a beneficial ther-apeutic effect(36).Applying metabolomics technologies,with the use of nuclear magnetic resonance and mass spectrometer–based stable isotope resolved metabolomics with13C-labeled glucose and glutamine,a study by Le and colleagues(36) documents that cancer cells use either glucose or glutamine, depending on the availability of the nutrients.Thisflexi-bility of cancer metabolism enables cancer cells to prolif-erate and survive even under the hypoxic and nutrient-deprived conditions,which are often encountered in the tumor microenvironment.Moreover,in hypoxia,they observed the enhanced conversion of glutamine to gluta-thione,an important reducing agent for control of the accumulation of mitochondrial ROS.Most importantly, this study uncovered a previously unsuspected glucose-independent glutamine-driven tricarboxylic acid(TCA) cycle.Cancer cells subjected to glucose deficiency and/or hypoxia would benefit from such glucose-independent TCA cycle activity in the tumor microenvironment.Cell growth and survival can be sustained by glutamine metabolism alone.In addition to the links between oncogenes and tumor suppressors to altered cancer cell metabolism,muta-tions in specific TCA cycle enzymes contribute to tumori-genesis of familial or spontaneously acquired cancers.The study by Mullen and colleagues(37)uncovered other metabolic reprogrammed pathways in cancer cells,which have mutations in complex I or complex III of the electron transport chain(ETC).These are often found in patient-derived renal carcinoma cells with mutations in FH,and also in pharmacologically ETC-inhibited cells with normal mitochondria.These cancer cells use glutamine-dependent reductive carboxylation generating acetyl-CoA for lipid synthesis.These processes use mitochondrial and cytosolic isoforms of NADPþ/NADPH-dependent IDH.The ETC-deficient cancer cells,like FH mutations,cannot grow without glutamine.Hence,depending on the genetic make-up,a cancer cell could be distinctively addicted to glucose or glutamine.Given that pancreatic cancers uniquely display increased levels offibrotic stroma,the pancreatic cancer cell environ-ment could be highly nutrient deficient(38,39).In this nutrient-deprived state,increased AMPK activity could trig-ger autophagy(21).The process of self-eating or autophagy provides starved cells a means to survive by recycling cel-lular components as bioenergetic substrates for energy production and building blocks.As such,certain metabolic hubs should be exploitable for therapy,particularly if a specific cancer type is"addicted"to that pathway.Metabolic enzymes are readily pharmacologically targetable;in fact, many historical clinically effective chemotherapeutic drugs were termed"antimetabolites."Seeking drugs that directly inhibit these new metabolic targets involved in cancer cell energy metabolism while sparing normal cells is among the most desirable goal to improve cancer therapy,especially for the treatment of pancreatic cancer.Blocking pancreatic cancer fuel supplyAddiction to glucose could be exploited through targeted inhibition of enzymes involved in glycolysis.One such target is the glycolytic pathway,in which the most consis-tent abnormality is its ultimate step of conversion of pyru-vate to lactic acid by lactate dehydrogenase A(LDHA)to regenerate NADþthat is required for the further glycolytic conversion of glucose to pyruvate to generate ATP.Recent studies(40,41)have targeted this phenotype of altered metabolism for therapy.Thefirst drug-like small molecule (called FX11)that inhibits LDHA was used as proof of concept for targeting aerobic glycolysis in cancer.This compound,7-benzyl-2,3-dihydroxy-6-methyl-4-n-propyl-1-napthoic acid,has shown an antitumorigenic effect in mouse models of human lymphoma and pancreatic cancer through the increased production of ROS and cell death (40).By blocking LDHA,FX11diminishes the ability of malignant cells to metabolize pyruvate to lactate,and halts the regeneration of NADþfor glycolysis processing.This study also showed a strong synergy effect in vitro and in vivo with the use of FX11in combination with FK866,an inhibitor of NADþbiosynthesis,which accentuates NADþdepletion.Besides the Warburg Effect,cancer cells also maintain mitochondrial oxidation of glutamine by glutaminase that converts glutamine to glutamate,which enters the TCA cycle as2-oxoglutarate.Two recent studies targeted glutaminolysis in cancer by a specific glutaminase inhibitor,bis-2-[5-(phe-nylacetamido)-1,3,4-thiadiazol-2-yl]ethyl sulfide(BPTES; Clin Cancer Res;18(16)August15,20124287ref.42).Thefirst study by Seltzer and colleagues(43) reported a preferable inhibition of mutant IDH1cell growth by BPTES as compared with the WT enzyme.Mutation at the R132residue of IDH1creates a novel enzyme function that produces2-HG from a-KG,which is from glutamate,a product of glutamine via glutaminase.Cancer cells with mutant IDH1become addicted to glutamine and heavily depend on glutaminase.The addition of exogenous a-KG rescued growth suppression of mutant IDH1cells by BPTES, which lowered glutamate and a-KG levels,inhibited gluta-minase activity,and increased glycolytic intermediates.How-ever,2-HG levels were unaffected by BPTES.This presents a potential therapeutic opportunity.The study by Wang and colleagues(44)provided another aspect of targeting mito-chondrial glutaminase activity inhibiting oncogenic trans-formation.They showed that glutaminase activity,which is dependent on Rho GTPases and NF-k B activity,increased in transformedfibroblasts and breast cancer cells.Targeting glutaminase activity by BPTES to inhibit oncogenic trans-formation had thus been shown,through a connection between Rho GTPase activation and cellular metabolism,to be a promising way forward.The importance of hypoxic glutamine metabolism in the study by Le and colleagues was also underscored by the antiproliferative therapeutic effect of BPTES on neoplastic cells in vitro and in a tumor xenograft model in vivo(36).In addition to the proof-of-concept studies suggesting the feasibility of targeting glucose or glutamine metabolism in pancreatic cancer,it has been noted that pancreatic cancers display significant autophagic activities for survival(45–49).In fact,Ras-transformed cells depend on autophagy for survival(50).Hence,inhibition of autophagy with the antimalarial agent chloroquine has resulted in significant preclinical responses of pancreatic cancer xenografts and allografts in treated mice as compared with control(49,51). Chloroquine also diminishes pancreatic tumorigenesis in a transgenic model(49).These studies suggest that2related and widely used agents with extremely favorable safety profiles,chloroquine or hydroxychloroquine,could have profound clinical effects.Indeed,there are now clinical trials testing this concept in pancreatic cancer.As for target-ing glycolysis or glutaminolysis,thefield is awaiting phar-maceutical companies to develop clinically safe,highly potent drugs to be tested in the clinic.Notwithstanding the inherent challenges for drug development,the concept of blocking the pancreatic cancer fuel supply provides a reasonable framework for the development of what is hoped to be a new class of anticancer agents.Future directionsAlthough cancer cells can exhibit unique metabolic path-ways,they also use the classic metabolic pathways of normal cells.This presents a great challenge to directly target met-abolic pathways,especially metabolic enzymes as drug targets.The success of small molecular agents depends on how much cancer cells are"addicted"to the fuel nutrition versus normal cells,as shown in the studies mentioned above.The combination of multiomics technologies will give a functional perspective of cancer progression,beyond genes and protein expression profiles.The extensive data obtained from metabolicflux will be mined to identify specific pathways active in the tumor compared with untransformed cells.These data are essential for understand-ing the metabolic activity in tumor tissue,especially how cancer cells can respond to different environmental condi-tions and how they respond to therapy to detect likely responders and nonresponders to a particular chemothera-peutic agent.This is highly desirable because it is important to avoid the use of cytotoxic drugs that have no benefit.The ultimate goal is to characterize and enable targeted selection of patients based on predicted metabolic responses.The metabolic signatures that correlate with sensitivity of pan-creatic cancers to metabolic inhibitors will also be used in the future to help us combine existing drugs to target multiple metabolic pathways and attack specific attributes of each patient’s cancer.In fact,metformin,which inhibits NADH dehydrogenase and mitochondrial respiration,has preclin-ical activity against pancreatic cancer xenografts(Kumar and colleagues,unpublished data)and is used in clinical trials. However,parameters that predict resistance or response remain poorly understood.Hence,defining the metabolic pathways of pancreatic cancer through metabolomics will pave the way for prediction of response and the identifica-tion of new enzyme targets for pancreatic cancer therapies.A major technical challenge in this arena is the heterogeneity of the pancreatic tumor tissue,which is laced with an extensivefibrotic stroma comprising of host immune cells. The potential for cancer cells to reprogram their metab-olism to bypass the targeted enzymatic step may occur and hence poses a challenge to metabolic therapy.This issue is especially significant given the interconnectivity of the cellular metabolic network.In combination with appropri-ate computational tools(e.g.,flux balance analysis),meta-bolomics offers a powerful way to identify possible"met-abolic escape routes."With the insight of this guide,we will eliminate these escape routes through rational combination therapies,for example,in combination with current anti-metabolites.This will allow for more cost-effective and personalized cancer treatment.Further complicating attempts at developing pancreatic cancer therapies,there is emerging evidence of pancreatic cancer stem cells in pancreatic cancers and these cells are responsible for drug resistance to standard chemotherapy, resulting in relapse and metastasis of pancreatic adenocar-cinoma(see review by Penchev and colleagues in this issue; ref.52).Therefore,recognizing the heterogeneity of multi-subpopulation of pancreatic tumors and understanding the distinguished metabolic modes of each are critical impor-tant for targeting of these subpopulations.Disclosure of Potential Conflicts of Interest No potential conflicts of interests were disclosed.Authors'ContributionsConception and design:A.MaitraAnalysis and interpretation of data(e.g.,statistical analysis,biosta-tistics,computational analysis):C.V.Dang Clin Cancer Res;18(16)August15,2012Clinical Cancer Research 4288Writing,review,and/or revision of the manuscript:A.Le,N.V.Rajesh-kumar,A.Maitra,C.V.DangGrant SupportAll authors supported by a Stand Up To Cancer Dream Team Transla-tional Cancer Research Grant,a Program of the Entertainment Industry Foundation(SU2C-AACR-DT107467). A.Le is supported by the Sol Goldman Pancreatic Cancer Research fund80028595and The Lustgarten Foundation fund90049125; C.V.Dang is supported by grants 5R01CA051497-21and5R01CA057341-20and A.Maitra is supported by R01CA113669,P01CA134292,and R01CA134767.Received March23,2012;revised June2,2012;accepted June27,2012; published OnlineFirst August15,2012.References1.Iacobuzio-Donahue CA,Velculescu VE,Wolfgang CL,Hruban RH.Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing.Clin Can-cer Res2012;18:4257–65.2.Feig C,Gopinathan A,Neesse A,Chan DS,Cook N,Tuveson DA.Thepancreas cancer microenvironment.Clin Cancer Res2012;18:4266–76.3.Koppenol WH,Bounds PL,Dang CV.Otto Warburg's contributions tocurrent concepts of cancer metabolism.Nat Rev Cancer2011;11: 325–37.4.Vander Heiden MG.Targeting cancer metabolism:a therapeutic win-dow opens.Nat Rev Drug Discov2011;10:671–84.5.VanderHeiden MG,Cantley LC,Thompson CB.Understanding theWarburg effect:the metabolic requirements of cell proliferation.Sci-ence2009;324:1029–33.6.Kroemer G,Pouyssegur J.Tumor cell metabolism:cancer's Achilles'heel.Cancer Cell2008;13:472–82.7.Garcia-Cao I,Song MS,Hobbs RM,Laurent G,Giorgi C,de Boer VC,,et al.Systemic elevation of PTEN induces a tumor-suppressive met-abolic state.Cell2012;149:49–62.8.Gaglio D,Soldati C,Vanoni M,Alberghina L,Chiaradonna F.Glutaminedeprivation induces abortive s-phase rescued by deoxyribonucleo-tides in k-ras transformedfibroblasts.PLoS One2009;4:e4715.9.Gaglio D,Metallo CM,Gameiro PA,Hiller K,Danna LS,Balestrieri C,et al.Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.Mol Syst Biol2011;7:523.10.Weinberg F,Hamanaka R,Wheaton WW,Weinberg S,Joseph J,LopezM,et al.Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity.Proc Natl Acad Sci U S A2010;107: 8788–93.11.King A,Selak MA,Gottlieb E.Succinate dehydrogenase and fumaratehydratase:linking mitochondrial dysfunction and cancer.Oncogene 2006;25:4675–82.12.Selak MA,Armour SM,MacKenzie ED,Boulahbel H,Watson DG,Mansfield KD,et al.Succinate links TCA cycle dysfunction to onco-genesis by inhibiting HIF-alpha prolyl hydroxylase.Cancer Cell 2005;7:77–85.13.Dang L,White DW,Gross S,Bennett BD,Bittinger MA,Driggers EM,et al.Cancer-associated IDH1mutations produce2-hydroxyglutarate.Nature2009;462:739–44.14.Lu C,Ward PS,Kapoor GS,Rohle D,Turcan S,Abdel-Wahab O,et al.IDH mutation impairs histone demethylation and results in a block to cell differentiation.Nature2012;483:474–8.15.Figueroa ME,Abdel-Wahab O,Lu C,Ward PS,Patel J,Shih A,et al.Leukemic IDH1and IDH2mutations result in a hypermethylation phenotype,disrupt TET2function,and impair hematopoietic differen-tiation.Cancer Cell2010;18:553–67.16.Xu W,Yang H,Liu Y,Yang Y,Wang P,Kim SH,et al.Oncometabolite2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases.Cancer Cell2011;19:17–30.17.DeBerardinis RJ,Cheng T.Q's next:the diverse functions of glutaminein metabolism,cell biology and cancer.Oncogene2010;29:313–24.18.Deberardinis RJ,Sayed N,Ditsworth D,Thompson CB.Brick by brick:metabolism and tumor cell growth.Curr Opin Genet Dev2008;18:54–61.19.Semenza GL.Hypoxia-inducible factors in physiology and medicine.Cell2012;148:399–408.20.Mathew R,White E.Autophagy in tumorigenesis and energy metab-olism:friend by day,foe by night.Curr Opin Genet Dev2011;21:113–9.21.Rabinowitz JD,White E.Autophagy and metabolism.Science2010;330:1344–8.22.Rubinsztein DC,Marino G,Kroemer G.Autophagy and aging.Cell2011;146:682–95.23.Egan D,Kim J,Shaw RJ,Guan KL.The autophagy initiating kinaseULK1is regulated via opposing phosphorylation by AMPK and mTOR.Autophagy2011;7:643–4.24.Mihaylova MM,Shaw RJ.The AMPK signalling pathway coordi-nates cell growth,autophagy and metabolism.Nat Cell Biol2011;13:1016–23.25.Finkel T.Signal transduction by reactive oxygen species.J Cell Biol2011;194:7–15.26.Finkel T.From sulfenylation to sulfhydration:what a thiolate needs totolerate.Sci Signal2012;5:pe10.27.Liu J,Cao L,Finkel T.Oxidants,metabolism,and stem cell biology.Free Radic Biol Med2011;51:2158–62.28.Brahimi-Horn MC,Bellot G,Pouyssegur J.Hypoxia and energetictumour metabolism.Curr Opin Genet Dev2011;21:67–72.29.Hanahan D,Weinberg RA.Hallmarks of cancer:the next generation.Cell2011;144:646–74.30.Gao X,Wang H,Yang JJ,Liu X,Liu ZR.Pyruvate kinase m2regulatesgene transcription by acting as a protein kinase.Mol Cell2012;45: 598–609.31.Warburg O.On the origin of cancer cells.Science1956;123:309–14.32.Von Hoff DD,Ramanathan RK,Borad MJ,Laheru DA,Smith LS,WoodTE,et al.Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer:a phase I/II trial.J Clin Oncol2011;29:4548–54.33.Ma WW,Jacene H,Song D,Vilardell F,Messersmith WA,Laheru D,et al.[18F]fluorodeoxyglucose positron emission tomography corre-lates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.J Clin Oncol2009;27:2697–704. 34.Birnbaum DJ,Adelaide J,Mamessier E,Finetti P,Lagarde A,MongesG,et al.Genome profiling of pancreatic adenocarcinoma.Genes Chromosomes Cancer2011;50:456–65.35.Dang CV.MYC on the path to cancer.Cell2012;149:22–35.36.Le A,Lane AN,Hamaker M,Bose S,Gouw A,Barbi J,et al.Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells.Cell Metab2012;15:110–21.37.Mullen AR,Wheaton WW,Jin ES,Chen PH,Sullivan LB,Cheng T,et al.Reductive carboxylation supports growth in tumour cells with defec-tive mitochondria.Nature2011;481:385–8.38.Hong SM,Park JY,Hruban RH,Goggins M.Molecular signatures ofpancreatic cancer.Arch Pathol Lab Med2011;135:716–27.39.Vincent A,Herman J,Schulick R,Hruban RH,Goggins M.Pancreaticncet2011;378:607–20.40.Le A,Cooper CR,Gouw AM,Dinavahi R,Maitra A,Deck LM,et al.Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression.Proc Natl Acad Sci U S A2010;107: 2037–42.41.Granchi C,Roy S,Giacomelli C,Macchia M,Tuccinardi T,Martinelli A,et al.Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A(LDH-A)as starvation agents against cancer cells.J Med Chem2011;54:1599–612.42.Robinson MM,McBryant SJ,Tsukamoto T,Rojas C,Ferraris DV,Hamilton SK,et al.Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide(BPTES).Biochem J2007;406:407–14.43.Seltzer MJ,Bennett BD,Joshi AD,Gao P,Thomas AG,Ferraris DV,et al.Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.Cancer Res2010;70:8981–7. Clin Cancer Res;18(16)August15,20124289。